Yahoo Italia Ricerca nel Web

Risultati di ricerca

1. www.researchgate.net › profile › Neil-HallidayNeil HALLIDAY | Speciality Registrar | MBBS, BSc - ResearchGate

   www.researchgate.net › profile › Neil-Halliday

   Neil HALLIDAY, Speciality Registrar | Cited by 1,904 | of Royal Free London NHS Foundation Trust, London (Royal Free) | Read 60 publications | Contact Neil HALLIDAY

2. Immagini

   • 
   • 
   • 
   • 
   • 

   Mostra tutto

3. www.ntu.ac.uk › about-us › staff-directoryStaff profile dynamic - Nottingham Trent University

   www.ntu.ac.uk › about-us › staff-directory

   • Cache

   Neil Halliday Senior Lecturer Nottingham School of Art & Design Email: neil.halliday@ntu.ac.uk; Phone: +44 (0)115 941 8418 Contact us +44 (0)115 848 2999 ...

4. ashpublications.org › blood › articleCTLA-4: a moving target in immunotherapy | Blood - American...

   ashpublications.org › blood › article

   • Cache

   4 gen 2018 · Cytotoxic T-lymphocyte antigen 4 (CTLA-4) (CD152) and CD28 are homologous receptors expressed by both CD4 + and CD8 + T cells, which mediate opposing functions in T-cell activation. Both receptors share a pair of ligands expressed on the surface of antigen-presenting cells (APCs).

   • Autore: Behzad Rowshanravan, Neil Halliday, David M. Sansom

   • Publish Year: 2018

5. pubmed.ncbi.nlm.nih.gov › 33363541CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T...

   pubmed.ncbi.nlm.nih.gov › 33363541

   8 dic 2020 · Abstract. CD80 and CD86 are expressed on antigen presenting cells and are required to engage their shared receptor, CD28, for the costimulation of CD4 T cells. It is unclear why two stimulatory ligands with overlapping roles have evolved. CD80 and CD86 also bind the regulatory molecule CTLA-4.

   • Autore: Neil Halliday, Cayman Williams, Alan Kennedy, Erin Waters, Anne M Pesenacker, Blagoje Soskic, Claudi...

   • Publish Year: 2020

6. pubmed.ncbi.nlm.nih.gov › 32794592Review article: experimental therapies in autoimmune hepatitis

   pubmed.ncbi.nlm.nih.gov › 32794592

   Abstract. Background: Current therapeutic options for autoimmune hepatitis (AIH) are limited by adverse events associated with corticosteroids and thiopurines and the limited evidence base for second- and third-line treatment options.

   • Autore: Neil Halliday, Neil Halliday, Jessica Katharine Dyson, Jessica Katharine Dyson, Douglas Thorburn, Do...

   • Publish Year: 2020

7. www.ntu.ac.uk › staff-profiles › art-designNeil Halliday - Nottingham Trent University

   www.ntu.ac.uk › staff-profiles › art-design

   • Cache

   Neil Halliday is a full-time Senior Lecturer teaching across all three years on the BA Graphic design course at NTU.

8. discovery.ucl.ac.uk › id › eprintPatient priorities in autoimmune hepatitis: the need for better

   discovery.ucl.ac.uk › id › eprint

   Background. Data show that patients with autoimmune hepatitis have significantly reduced quality-of-life and. that corticosteroids carry marked side effects. . Aims. This study explored patients’ experiences of autoimmune hepatitis and its treatments; key aspects.